FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Green

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Michael D Green; P A Francis; V Gebski; V Harvey; C Karapetis; A Chan; R Snyder; A Fong; Russell L Basser; J F Forbes
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.
S Wong; Mark A Rosenthal; R deBoer; Michael D Green; Richard M Fox
Five years managing metastatic non-small cell lung cancer: experience at a teaching hospital.
Dishan H Gunawardana; Russell L Basser; Ian D Davis; Jonathan Cebon; Paul Mitchell; Craig Underhill; Trevor J Kilpatrick; Katrina Reardon; Michael D Green; Peter Bardy; Pene Amor; David Crump; Siobhan Ng; Roger L Nation; C Glenn Begley
A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Green (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Michael D Green; P A Francis; V Gebski; V Harvey; C Karapetis; A Chan; R Snyder; A Fong; Russell L Basser; J F Forbes
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(11):1813-7.
2004: S Wong; Mark A Rosenthal; R deBoer; Michael D Green; Richard M Fox
Five years managing metastatic non-small cell lung cancer: experience at a teaching hospital.
Internal medicine journal 2004;34(8):458-63.
2003: Dishan H Gunawardana; Russell L Basser; Ian D Davis; Jonathan Cebon; Paul Mitchell; Craig Underhill; Trevor J Kilpatrick; Katrina Reardon; Michael D Green; Peter Bardy; Pene Amor; David Crump; Siobhan Ng; Roger L Nation; C Glenn Begley
A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2056-65.
2002: Mark A Rosenthal; D Rischin; G McArthur; K Ribbons; B Chong; J Fareed; Guy C Toner; Michael D Green; Russell L Basser
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):770-6.
2001: Mark A Rosenthal; B Kavar; JS Hill; DJ Morgan; R L Nation; Stanley Stylli; Russell L Basser; Shannon Uren; H Geldard; Michael D Green; S B Kahl; Andrew H Kaye
Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):519-24.
2000: Russell L Basser; Craig Underhill; I Davis; Michael D Green; Jonathan Cebon; John Zalcberg; J MacMillan; Brian Cohen; J Marty; Richard M Fox; C Glenn Begley
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(15):2852-61.
2000: Ian D Davis; Darryl W Maher; Jonathan Cebon; Michael D Green; Richard M Fox; JJ McKendrick; M E Rybak; A W Boyd
A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer.
Growth factors (Chur, Switzerland) 2000;17(4):287-300.
1999: K Clarke; Russell L Basser; Craig Underhill; P Mitchell; J Bartlett; Lawrence Cher; Michael Findlay; D Dalley; M Pell; M Byrne; H Geldard; JS Hill; D Maher; Richard M Fox; Michael D Green; Andrew H Kaye
KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2579-84.
1999: S M Talbot; David Westerman; Andrew P Grigg; Guy C Toner; M Wolf; J Bishop; JJ McKendrick; John Zalcberg; J Levi; Richard M Fox; Michael D Green
Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):907-14.
1999: Russell L Basser; L Bik To; J P Collins; C Glenn Begley; dorothy Keefe; Jonathan Cebon; John Bashford; Simon Durrant; Jeff Szer; D Kotasek; CA Juttner; I Russell; Darryl W Maher; Ian N Olver; William Patrick Sheridan; Richard M Fox; Michael D Green
Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):82-92.
1999: Russell L Basser; R Abraham; L Bik To; Richard M Fox; Michael D Green
Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(1):53-8.
1998: K Clarke; Russell L Basser; D Maher; DJ Morgan; Jonathan Cebon; Richard M Fox; JS Hill; C Alt; J Bartlett; H Geldard; Andrew H Kaye; Michael D Green
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2181-7.
1998: Russell L Basser; L Bik To; C Glenn Begley; D Maher; CA Juttner; Jonathan Cebon; R Mansfield; Ian N Olver; G Duggan; Jeff Szer; J Collins; B Schwartz; J Marty; Dora M Menchaca; William Patrick Sheridan; Richard M Fox; Michael D Green
Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1899-908.
1998: DJ Morgan; JS Hill; K Clarke; Stanley Stylli; SJ Park; Jonathan Cebon; Russell L Basser; Andrew H Kaye; H Geldard; Darryl W Maher; Michael D Green
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease.
Cancer chemotherapy and pharmacology 1998;41(5):423-6.
1997: C Glenn Begley; Russell L Basser; R Mansfield; B Thomson; W R Parker; JE Layton; Bik To; Jonathan Cebon; William Patrick Sheridan; Richard M Fox; Michael D Green
Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans.
Blood 1997;90(9):3378-89.
1997: Michael D Green
Oral bisphosphonates and malignancy.
The Medical journal of Australia 1997;167(4):211-2.
1997: Russell L Basser; John Rasko; K Clarke; Jonathan Cebon; Michael D Green; Andrew P Grigg; John Zalcberg; Brian Cohen; J O'Byrne; Dora M Menchaca; Richard M Fox; C Glenn Begley
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Blood 1997;89(9):3118-28.
1997: DJ Morgan; JS Hill; K Clarke; Stanley Stylli; SJ Park; Jonathan Cebon; Russell L Basser; Andrew H Kaye; H Geldard; Darryl W Maher; Michael D Green
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
Cancer chemotherapy and pharmacology 1997;40(3):202-8.
1996: Russell L Basser; John Rasko; K Clarke; Jonathan Cebon; Michael D Green; S Hussein; C Alt; Dora M Menchaca; Dianne Tomita; J Marty; Richard M Fox; C Glenn Begley
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Lancet 1996;348(9037):1279-81.
1996: C J O'Malley; John Rasko; Russell L Basser; K M McGrath; Jonathan Cebon; A P Grigg; W Hopkins; B Cohen; J O'Byrne; Michael D Green; Richard M Fox; M C Berndt; C Glenn Begley
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.
Blood 1996;88(9):3288-98.
1994: Russell L Basser; M M Sobol; G Duggan; Jonathan Cebon; M A Rosenthal; G Mihaly; Michael D Green
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(8):1659-66.
1994: William Patrick Sheridan; C Glenn Begley; L B To; A Grigg; Jeff Szer; D Maher; Michael D Green; P A Rowlings; K M McGrath; Jonathan Cebon
Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
Bone marrow transplantation 1994;14(1):105-11.
1992: P M Alderton; J Gross; Michael D Green
Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Cancer research 1992;52(1):194-201.
1992: Russell L Basser; Michael D Green; William Patrick Sheridan; Richard M Fox
Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancer.
Cancer chemotherapy and pharmacology 1992;30(2):161-3.
1991: Russell L Basser; GJ Lieschke; William Patrick Sheridan; Richard M Fox; Michael D Green
Recombinant alpha-2b interferon in patients with malignant carcinoid tumour.
Australian and New Zealand journal of medicine 1991;21(6):875-8.
1990: S A Tjuljandin; R G Doig; M M Sobol; D M Watson; William Patrick Sheridan; G Morstyn; G Mihaly; Michael D Green
Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
Cancer research 1990;50(16):5095-101.
1990: P Alderton; J Gross; Michael D Green
Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Cancer research 1990;50(16):5136-42.
1989: William Patrick Sheridan; G Morstyn; M Wolf; A Dodds; J Lusk; D Maher; Judith E Layton; Michael D Green; L Souza; Richard M Fox
Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.
Lancet 1989;2(8668):891-5.
1989: William Patrick Sheridan; A W Boyd; Michael D Green; D M Russell; R J Thomas; K M McGrath; S L Vaughan; J D Scarlett; J D Griffiths; G N Brodie
High-dose chemotherapy with busulphan and cyclophosphamide and bone-marrow transplantation for drug-sensitive malignancies in adults: a preliminary report.
The Medical journal of Australia 1989;151(7):379-86.